Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection
Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection
复制标题
2年或更长时间的干扰素治疗可降低慢性丙型肝炎病毒感染患者的肝癌发生率
作者：
Y. Arase;K. Ikeda;A. Tsubota;F. Suzuki;Yoshiyuki Suzuki;S. Saitoh;M. Kobayashi;N. Akuta;T. Someya;T. Hosaka;H. Sezaki;M. Kobayashi;H. Kumada
目的：本临床研究的目的是确定长期使用干扰素（IFN）对慢性丙型肝炎患者肝细胞癌（HCC）发病率的影响，而无需通过干扰素治疗根除丙型肝炎病毒（HCV）。方法：经活检证实为中度或重度分期、HCV 基因型 1b、高病毒载量超过 1 MEq/ml（兆当量每毫升）的慢性肝炎患者，每天接受 6 MU 天然 IFN-α，持续 2-8 周，随后每周 3 次，持续 16-22 周，作为初始 IFN 治疗，并且在 IFN 给药期间 HCV RNA 呈阳性的患者人数为 131。 47 131 名患者在初始 IFN 治疗后继续接受 IFN 治疗（长期 IFN 组，剂量 3 或 6 MU，每周两次或三次，持续 1.5-10.5 年，中位 4.0 年），而 84 名患者除了最初的 6 个月疗程外，没有接受任何 IFN 治疗（无添加 IFN 组）。对患者进行前瞻性监测，并检查 HCC 的累积发病率和 HCC 的危险因素。结果：长期 IFN 组和不添加 IFN 组的 5 年和 10 年 HCC 累积率分别为 1.9 和 6.4%、1.9 和 26.8%。 Cox回归分析显示，不加IFN组患者发生HCC的相对风险是长期IFN组患者的8.72倍。结论：慢性HCV感染患者长期接受IFN治疗可有效预防肝癌的发生。
Objective: The purpose of this clinical study was to determine the effect of long-term interferon (IFN) administration on the incidence of hepatocellular carcinomas (HCC) in chronic hepatitis C patients, without eradication of hepatitis C virus (HCV) by IFN therapy. Methods: The number of patients with biopsy-proven chronic hepatitis with moderate or severe staging, HCV genotype 1b, a high viral load exceeding 1 MEq/ml (mega equivalents per milliliter), who received 6 MU of natural IFN-α daily for 2–8 weeks, followed by three times/week for 16–22 weeks, as initial IFN therapy, and positivity for HCV RNA during IFN administration was 131. 47 of the 131 patients continued to be treated with IFN (long-term IFN group, dose 3 or 6 MU twice or three times weekly for 1.5–10.5 years, median 4.0 years) after initial IFN therapy, while 84 patients did not receive any IFN therapy apart from the initial 6-month course (no-add-IFN group). The patients were prospectively monitored, and the cumulative incidence of HCC and risk factors for HCC were examined. Results: The 5- and 10-year cumulative rates of HCC were 1.9 and 6.4% and 1.9 and 26.8% for long-term IFN and no-add-IFN groups, respectively. Cox regression analysis indicated that the relative risk of HCC in the patients of the no-add-IFN group was 8.72 times of that in patients of the long-term IFN group. Conclusion: Long-term IFN therapy in patients with chronic HCV infection is effective in preventing hepatocarcinogenesis.
影响因子：
8
作者：
Masaya Shigeno;K. Nakao;T. Ichikawa;Kasumi Suzuki;A. Kawakami;S. Abiru;Seiji Miyazoe;Y. Nakagawa;H. Ishikawa;K. Hamasaki;K. Nakata;N. Ishii;K. Eguchi
通讯作者：
Masaya Shigeno;K. Nakao;T. Ichikawa;Kasumi Suzuki;A. Kawakami;S. Abiru;Seiji Miyazoe;Y. Nakagawa;H. Ishikawa;K. Hamasaki;K. Nakata;N. Ishii;K. Eguchi
影响因子：
158.5
作者：
McHutchison, JG;Gordon, SC;Albrecht, JK
通讯作者：
Albrecht, JK